Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
1. V-DIFFERENCE study shows Leqvio improves LDL-C goals significantly versus placebo. 2. 85% of patients on Leqvio met LDL-C targets in 90 days, reducing muscle pain. 3. Study confirms lower muscle-related side effects in patients using Leqvio. 4. Data supports Leqvio's potential to transform cardiovascular care, addressing patient adherence. 5. V-DIFFERENCE's findings will be presented at the 2025 ESC Congress.